doi:10.3969/j.issn.1673-8640.2017.04.014

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 17

[1]	LAMB R,BONUCCELLI G,OZSVáRI B,et al. Mitochondrial mass,a new metabolic biomarker for stem-like cancer cells:understanding WNT/FGF-driven anabolic signaling[J]. Oncotarget,2015,6(31):30453-30471.
[2]	BAO L,CARDIFF R D,STEINBACH P,et al.Multipotent luminal mammarycancer stem cells model tumor heterogeneity[J]. Breast Cancer Res,2015,17(1):137.
[3]	ASPARUHOVA M B,SECONDINI C,RüEGG C,et al. Mechanism of irradiation-induced mammary cancer metastasis:a role for SAP-dependent Mkl1 signaling[J]. Mol Oncol,2015,9(8):1510-1527.
[4]	LAKSHMINARAYANAN V,THOMPSON P,WOLFERT M A,et al.Immune recognition of tu-mor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine[J]. Proc Natl Acad Sci U S A,2012,109(1):261-266.
[5]	CAMPOS L C,LAVALLE G E,ESTRELA-LIMA A,et al.CA15. 3,CEA and LDH in dogs with malignant mammary tumors[J]. J Vet Intern Med,2012,26(6):1383-1388.
[6]	王建国,王贯宇,吴煜龙,等. 乳腺癌肿瘤标志物CA15-3和CEA联合检测的临床意义[J]. 医学研究与教育,2011,28(1):35-37.
[7]	宋现让,王丽莉,丁艳涛,等. CA15-3、CA19-9、CA24-2、CA125和CEA在乳腺癌诊断中的应用[J]. 癌症,2001,20(3):328-329.
[8]	GION M,MIONE R,LEON A E,et al.Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer[J]. Clin Chem,1999,45(5):630-637.
[9]	贾晓娟,许建林,杨琪,等. CA15-3在乳腺癌中的临床意义[J]. 陕西肿瘤医学,2001,9(4):236-237.
[10]	詹红泉. CEA CA153 CA125 CA199 CYFRA21-1联合检测乳腺癌的诊断价值[J]. 浙江临床医学,2016,18(3):555-556.
[11]	徐庆华,舒向芳,胡涛. 血清CA15-3、CEA 和PRL联合检测在乳腺癌早期诊断中的意义[J]. 中国实验诊断学,2015,19(4):647-648.
[12]	易琳,刘兴明,林丁,等. 血清CA153、CA125、CEA联合检测在乳腺癌诊断中的价值[J]. 重庆医科大学学报,2012,37(9):802-805.
[13]	吴祥德. 乳腺疾病诊治[M]. 北京:人民卫生出版社,2000:170-176.
[14]	UIBRICH E J,LEBRECHT A,SCHNEIDER I,et a1. Serum parameters of iron metabolism in patients with breast cancer[J]. Anticancer Res,2003,23(6D):5107-5109.
[15]	GILLESPIE M T,THOMAS R J,PU Z Y,et al.Calcitonin receptors,bone sialoprotein and osteopontin are expressed in primary breast cancers[J].Int J Cancer,1997,73(6):812-815.
[16]	史春云,王淑仙,冯惠清. 肿瘤标志物CA15-3、CEA和CA125与乳腺癌关系的研究进展[J]. 医学研究与教育,2012,29(3):49-52.
[17]	陈士华. 联合检测CA15-3、CA125、CEA对乳腺癌的临床价值探讨[J]. 检验医学,2013,28(3):235-237.

组别	CA153（U/mL）	CEA（ng/mL）	铁蛋白（ng/mL）	降钙素（pg/mL）
正常对照组	7.9±4.3	1.5±0.2	35.8（22.7~46.4）	1.2±0.1
乳腺良性肿块组	11.9±4.6^***	2.1±0.9^***	72.9（31.5~105.4）^**	2.2±0.5^*
乳腺癌组	15.2±10.8^***	2.2±1.3^**	109.6（51.75~197.2）^***#	3.5±0.7^***

组别	CA153（U/mL）	CEA（ng/mL）	铁蛋白（ng/mL）	降钙素（pg/mL）
正常对照组	7.9±4.3	1.5±0.2	35.8（22.7~46.4）	1.2±0.1
乳腺良性肿块组	11.9±4.6^***	2.1±0.9^***	72.9（31.5~105.4）^**	2.2±0.5^*
乳腺癌组	15.2±10.8^***	2.2±1.3^**	109.6（51.75~197.2）^***#	3.5±0.7^***

病理分级	CA153（U/mL）	CEA（ng/mL）	铁蛋白（ng/mL）	降钙素（pg/mL）
Ⅰ~Ⅱ级	14.9±8.6	2.2±0.8	98.9（54.5~183.4）	3.4±0.3
Ⅲ级	15.3±9.8	2.3±1.0	100.6（50.05~199.2）	3.6±0.6

病理分级	CA153（U/mL）	CEA（ng/mL）	铁蛋白（ng/mL）	降钙素（pg/mL）
Ⅰ~Ⅱ级	14.9±8.6	2.2±0.8	98.9（54.5~183.4）	3.4±0.3
Ⅲ级	15.3±9.8	2.3±1.0	100.6（50.05~199.2）	3.6±0.6

项目	敏感性	特异性	阳性似然比	阴性似然比	ROC曲线下面积（95%可信区间）
CA153	54.6	90.7	8.7	0.49	0.663（0.561~0.766）
CEA	41.2	92.5	5.5	0.64	0.557（0.471~0.643）
铁蛋白	71.1	68.5	14.7	0.25	0.829（0.768~0.890）
降钙素	22.5	73.2	4.6	0.71	0.531（0.436~0.626）
联合检测	81.2	95.0	16.3	0.20	0.871（0.817~0.926）

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 17

Related Articles 15

Recommended Articles

Metrics

[1]	GAO Zikang, CHEN Jing. Construction of a nomogram prediction model for the prognosis of patients with depressive disorder based on the characteristics of peripheral blood lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(12): 1146-1152.
[2]	WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV，SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites [J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[5]	ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
[6]	ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p，miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma [J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
[7]	LI Song, XIANG Xu. Risk factors for poor prognosis in elderly patients with severe fever and thrombocytopenia syndrome and their clinical significance [J]. Laboratory Medicine, 2025, 40(12): 1183-1189.
[8]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[9]	. [J]. Laboratory Medicine, 2025, 40(12): 1197-1202.
[10]	. [J]. Laboratory Medicine, 2025, 40(12): 1216-1221.
[11]	. [J]. Laboratory Medicine, 2025, 40(12): 1222-1226.
[12]	BAO Wen. Application and prospect of microsatellite instability determination in tumor diagnosis and treatment [J]. Laboratory Medicine, 2025, 40(12): 1227-1231.
[13]	XIONG Ying, GUO Wei. From generic to personalized：the evolution and frontiers of indirect methods for establishing reference interval [J]. Laboratory Medicine, 2025, 40(11): 1035-1041.
[14]	CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052.
[15]	LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP，CEA，CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058.